Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC (POPPY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03813836
Recruitment Status : Recruiting
First Posted : January 23, 2019
Last Update Posted : July 9, 2019
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
University College, London

Brief Summary:
A single-arm phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status of 2 with recurrent or metastatic squamous cell carcinoma of the head and neck. Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months

Condition or disease Intervention/treatment Phase
Metastatic Head and Neck Squamous Cell Carcinoma Recurrent Head and Neck Squamous Cell Carcinoma Drug: Pembrolizumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 65 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial to Assess the Efficacy and Safety Profile of Pembrolizumab in Patients With Performance Status 2 With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Actual Study Start Date : July 5, 2019
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: pembrolizumab + best supportive care
Best supportive care and pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
Drug: Pembrolizumab
Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
Other Name: Keytruda




Primary Outcome Measures :
  1. Disease control rate at 24 weeks assessed using RECIST v1.1 [ Time Frame: 24 weeks after registration ]
    Disease control rate (proportion of patients with CR, PR or SD) assessed using RECIST v1.1


Secondary Outcome Measures :
  1. Disease control rate assessed using RECIST v1.1 [ Time Frame: 12 months after registration ]
    Disease control rate (proportion of patients with CR, PR or SD) assessed using RECIST v1.1

  2. Best Response Rate- measured using the change from baseline tumour size. Assessed using iRECIST. [ Time Frame: 6 months after registration ]
    Best Response Rate, defined as proportion of patients who have a CR or PR as their best response, measured using the change from baseline tumour size, assessed using iRECIST

  3. Clinical Benefit Rate -defined as patient's best response rate lasting at least 18 weeks [ Time Frame: From start of treatment to 30 months post start of treatment ]
    Clinical Benefit Rate, defined as proportion patients who have achieved CR, PR or SD as their best response lasting at least 18 weeks

  4. Duration of Response- defined as the time from first documented evidence of CR or PR until disease progression or death. [ Time Frame: From start of treatment to 30 months post start of treatment ]
    Duration of Response, defined as the time from first documented evidence of CR or PR until disease progression or death

  5. Time to Progression -defined as time from registration to the first documented disease progression [ Time Frame: From registration to 30 months post start of treatment ]
    Time to Progression, defined as time from registration to the first documented disease progression

  6. Progression Free Survival defined as the time from registration to the first documented disease progression or death due to any cause, whichever occurs first. [ Time Frame: From registration to 30 months post start of treatment ]
    Progression Free Survival, defined as the time from registration to the first documented disease progression or death due to any cause, whichever occurs first.

  7. Overall Survival- defined as the time from registration to death due to any cause. [ Time Frame: From registration to 30 months post start of treatment ]
    Overall Survival, defined as the time from registration to death due to any cause.

  8. Frequency and severity of adverse events- throughout the patient's treatment and until 6 months after completion of trial treatment. [ Time Frame: From date of registration until 6 months after completion of trial treatment ]
    Frequency and severity of adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Histologically confirmed recurrent or metastatic squamous cell carcinoma of the head and neck that is considered incurable by local therapies.
  2. Measurable disease evaluated by RECIST v1.1
  3. WHO performance status of 2
  4. Life expectancy of at least 12 weeks
  5. Aged ≥ 18 years of age
  6. Adequate Bone marrow function:

    • Absolute neutrophils grade 0 or 1 (using CTCAE v5)
    • Platelets grade 0 or 1
    • Haemoglobin grade 0 or 1
  7. Adequate renal function:

    Creatinine grade 0 or 1 Calculated glomerular filtration rate (GFR) ≥ 50 mL/min estimated using validated creatinine clearance calculation (e.g. Cockcroft-Gault or Wright formula). If calculated GFR is < 50 mL/min then an isotope GFR assessment (Cr51-EDTA or 99mTc-DTPA) should be performed. If an isotope GFR test is unavailable an estimation from 24 hour urine collection may be used

  8. Adequate liver function:

    Serum bilirubin grade 0 or 1 AST and ALT grade 0 or 1 (up to grade 2 for patients with liver metastases)

  9. Willing to use contraception for the duration of trial treatment and for 120 days after completion of treatment
  10. Willing to have a new biopsy, if site of disease is accessible and considered safe to biopsy by investigator If newly obtained samples cannot be obtained (e.g. inaccessible disease or patient safety concern) sites may submit archival tissue only upon agreement from the sponsor
  11. Able to give informed consent, indicating that the patient has been informed of and understands the experimental nature of the study, possible risks and benefits, trial procedures, and alternative options
  12. Willing and able to comply with the protocol for the duration of the study, including the treatment plan, investigations required and follow up visits

Exclusion Criteria:

  1. Patients with undifferentiated nasopharyngeal or sino-nasal cancers
  2. Disease suitable for treatment with curative intent
  3. Prior therapy with an anti-PD-1, anti-PD-L1 or anti-PD-L2 agent
  4. Any investigational agents within 4 weeks prior to registration
  5. Anti-cancer monoclonal antibody therapy within 4 weeks prior to registration
  6. Chemotherapy, targeted small molecule therapy, or radiotherapy within 2 weeks prior to registration
  7. Patients with concurrent or previous malignancy that could compromise assessment of the primary or secondary endpoints of the trial
  8. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment
  9. Grade 3 or 4 peripheral neuropathy
  10. Any serious and/or unstable pre-existing medical, psychiatric or other condition that, in the treating clinician's judgment, could interfere with patient safety or obtaining informed consent
  11. Active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they:

    Are stable, without evidence of progression for at least four weeks prior to the first dose of trial treatment Have no evidence of new or enlarging brain metastases Have no evidence of leptomeningeal disease Are not using steroids for at least 7 days prior to trial treatment

  12. Has a known history of or is positive for hepatitis B (hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (hepatitis C virus [HCV] RNA [qualitative] is detected) NB: Without known history, testing is required to determine eligibility. Hepatitis C antibody testing is allowed for screening purposes in sites where HCV RNA is not part of standard of care
  13. Immunocompromised patients (e.g. known HIV positive status)*
  14. Prior organ transplantation including allogenic stem-cell transplantation
  15. Has a history of (non-infectious) pneumonitis that required steroids, or current pneumonitis
  16. Active infection requiring systemic therapy
  17. Has received a live vaccine within 30 days prior to registration (seasonal flu vaccines that do not contain live virus are permitted)
  18. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment (NB: the use of physiologic doses of corticosteroids may be approved after consultation with UCL CTC)
  19. Active autoimmune disease that might deteriorate when receiving an immune-stimulatory agent. Patients with the following are eligible:

    Autoimmune-related hyperthyroidism or autoimmune-related hypothyroidism who are in remission or on a stable dose of thyroid-replacement hormone Vitiligo Psoriasis

  20. Current use of immunosuppressive medication, except for the following:

intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection) Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisolone or equivalent (after approval by UCL CTC) Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)

*Testing for HIV for the POPPY trial is not mandatory, however if this test has been done the result should be known prior to registration.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03813836


Contacts
Layout table for location contacts
Contact: Sarah Pearce 020 7679 9392 ctc.poppy@ucl.ac.uk
Contact: Sharon Forsyth 020 7679 9264 ctc.poppy@ucl.ac.uk

Locations
Layout table for location information
United Kingdom
University College London Hospital Recruiting
London, United Kingdom
Sponsors and Collaborators
University College, London
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Principal Investigator: Martin Forster, FRCP PhD University College, London

Layout table for additonal information
Responsible Party: University College, London
ClinicalTrials.gov Identifier: NCT03813836     History of Changes
Other Study ID Numbers: UCL/17/0396
First Posted: January 23, 2019    Key Record Dates
Last Update Posted: July 9, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University College, London:
Head and Neck Cancer
Metastatic Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma
Pembrolizumab

Additional relevant MeSH terms:
Layout table for MeSH terms
Pembrolizumab
Carcinoma
Carcinoma, Squamous Cell
Squamous Cell Carcinoma of Head and Neck
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Squamous Cell
Head and Neck Neoplasms
Neoplasms by Site
Antineoplastic Agents, Immunological
Antineoplastic Agents